Gut · 2014 · 74 citations · 37 references
MedicineOncologySurgeryCost-effectiveness AnalysisEarly DetectionGastrointestinal OncologyCost-effectiveness ModelingEconomic EvaluationEsophageal CancerGastroesophageal Reflux DiseaseHealthcare Cost AnalysisMarkov ModelingBarrett Esophagus DysplasiaBarrett Esophagus SurveillanceCost-effectivenessEndoscopic Surgical ResectionEsophageal SurveillanceManagement Of Barrett's EsophagusProspective Cohort DataProspective Cohort Surveillance
OBJECTIVE: Surveillance is recommended for Barrett's oesophagus (BO) to detect early oesophageal adenocarcinoma (OAC). The aim of this study was to evaluate the cost-effectiveness of surveillance. DESIGN: We included 714 patients with long-segment BO in a multicentre prospective cohort study and used a multistate Markov model to calculate progression rates from no dysplasia (ND) to low-grade dysplasia (LGD), high-grade dysplasia (HGD) and OAC. Progression rates were incorporated in a decision-analytic model, including costs and quality of life data. We evaluated different surveillance intervals for ND and LGD, endoscopic mucosal resection (EMR), radiofrequency ablation (RFA) and oesophagectomy for HGD or early OAC and oesophagectomy for advanced OAC. The incremental cost-effectiveness ratio (ICER) was calculated in costs per quality-adjusted life-year (QALY). RESULTS: The annual progression rate was 2% for ND to LGD, 4% for LGD to HGD or early OAC and 25% for HGD or early OAC to advanced OAC. Surveillance every 5 or 4 years with RFA for HGD or early OAC and oesophagectomy for advanced OAC had ICERs of €5.283 and €62.619 per QALY for ND. Surveillance every five to one year had ICERs of €4.922, €30.067, €32.531, €41.499 and €75.601 per QALY for LGD. EMR prior to RFA was slightly more expensive, but important for tumour staging. CONCLUSIONS: Based on a Dutch healthcare perspective and assuming a willingness-to-pay threshold of €35.000 per QALY, surveillance with EMR and RFA for HGD or early OAC, and oesophagectomy for advanced OAC is cost-effective every 5 years for ND and every 3 years for LGD.
37
Radiofrequency Ablation in Barrett's Esophagus with Dysplasia
Nicholas J. Shaheen, Prateek Sharma, Bergein F. Overholt et al. · New England Journal of Medicine · 2009 · 1.4K citations · Full text
Incidence of Adenocarcinoma among Patients with Barrett's Esophagus
Frederik Hvid‐Jensen, Lars Pedersen, Asbjørn Mohr Drewes et al. · New England Journal of Medicine · 2011 · 1.4K citations · Full text